Genexine’s COVID-19 drug to begin phase 1 trial in Korea - (The Korea Herald via NewsPoints Desk)

  • Genexine's COVID-19 treatment candidate GX-17 was given the Korean drug authority's approval on Friday to proceed to Phase I trials, as reported The Korea Herald.
     

  • GX-17 is a protein drug recombining human IL-7 and hybrid Fc, which the company had been developing as an anti-cancer treatment. 

To read more NewsPoints articles, click here.

Reference Articles